Akari Therapeutics (AKTX) Price & Analysis

Compare

305 Followers

AKTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.57 - $3.15

Previous CloseN/A

Volume16.29K

Average Volume (3M)354.89K

Market Cap

$34.25M

Enterprise Value$35.60M

Total Cash (Recent Filing)$2.71M

Total Debt (Recent Filing)$1.55M

Price to Earnings (P/E)―

Beta0.61

Next Earnings

Apr 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding32,612,576

10 Day Avg. Volume515,204

30 Day Avg. Volume354,895

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.04

Enterprise Value/Revenue1.37K

Enterprise Value/Gross Profit2.74K

Enterprise Value/Ebitda-2.61

Forecast

1Y Price Target

$4.53

Price Target Upside331.43% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Drug DevelopmentAkari Therapeutics is rated as a Buy with a price target of $5.00.

Pipeline PotentialAkari's ADCs deliver PH1, a novel spliceosome inhibitor that induces both cytotoxicity and neoantigen production, potentially avoiding toxicities associated with microtubule inhibitors and DNA-damaging agents.

Bears Say

Capital NeedsThe financial overhang may weigh on the stock until the company is able to secure additional funds.

Financial RiskThe company's weak balance sheet may present a significant risk.

Akari Therapeutics News

Akari Therapeutics announces preclinical data on PH1

Akari Therapeutics (AKTX) announced key preclinical data demonstrating the potential of its novel antibody drug conjugate, ADC, spliceosome...

15d ago

AKTX

Akari Therapeutics Stock (AKTX) Rises after Filing Patent for Novel Cancer Therapy

Biotech company Akari Therapeutics’ ($AKTX) shares, which have plunged about 35% over the past three months, trended upward...

22d ago

AKTX

Akari files for patent on ADC platform using spliceosome payload PH1

Akari Therapeutics (AKTX) has filed a provisional patent application with the United States Patent and Trademark Office covering...

22d ago

AKTX

Akari Therapeutics Completes August 2025 Notes Offering

The latest announcement is out from Akari Therapeutics ( ($AKTX) ). Akari Therapeutics successfully completed the issuance of...

10d ago

AKTX

Akari Therapeutics Reveals Promising Preclinical Data for PH1

Akari Therapeutics ( ($AKTX) ) has shared an update. Akari Therapeutics announced a significant amendment to its convertible...

14d ago

AKTX

Innovative Cancer Treatment Approach Drives Buy Rating for Akari Therapeutics

Akari Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from...

14d ago

AKTX

Akari Therapeutics’ Strategic Shift and Innovative ADC Platform Earns Buy Rating Despite Financial Constraints

Akari Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sean Lee CFA...

1M ago

AKTX

Akari Therapeutics Enters Share Purchase Agreement

The latest update is out from Akari Therapeutics ( ($AKTX) ). On August 29, 2025, Akari Therapeutics entered...

1M ago

AKTX

Akari Therapeutics Cancels Peak Bio Note and Loan

Akari Therapeutics ( ($AKTX) ) has issued an announcement. Akari Therapeutics has announced a Peak Bio Note and...

2M ago

AKTX

Akari Therapeutics Releases Updated Investor Presentation

An update from Akari Therapeutics ( ($AKTX) ) is now available. On August 19, 2025, Akari Therapeutics, Plc...

2M ago

AKTX

Buy Rating for Akari Therapeutics: Promising ADC Innovations and Growth Potential in Oncology

Jason McCarthy, an analyst from Maxim Group, reiterated the Buy rating on Akari Therapeutics. The associated price target...

2M ago

AKTX

Morning Movers: Under Armour sinks following second quarter earnings

Stock futures are edging higher amid growing expectations that the Federal Reserve may move toward dovish policies, spurred...

2M ago

AMR

Akari Therapeutics reports Q2 EPS (86c) vs. (81c) last year

“In the second quarter of 2025, we continued to build on the strong momentum established with the announcement...

2M ago

AKTX

Akari Therapeutics sees cash runway into 2028

Akero’s cash, cash equivalents and short and long-term marketable securities as of June 30, 2025, were $1,086.2 million....

2M ago

AKTX

AKTX FAQ

What was Akari Therapeutics PLC (ADR)’s price range in the past 12 months?

Akari Therapeutics PLC (ADR) lowest stock price was $0.57 and its highest was $3.15 in the past 12 months.

What is Akari Therapeutics PLC (ADR)’s market cap?

Akari Therapeutics PLC (ADR)’s market cap is $34.25M.

When is Akari Therapeutics PLC (ADR)’s upcoming earnings report date?

Akari Therapeutics PLC (ADR)’s upcoming earnings report date is Apr 07, 2026 which is in 180 days.

How were Akari Therapeutics PLC (ADR)’s earnings last quarter?

Akari Therapeutics PLC (ADR) released its earnings results on Sep 25, 2025. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.09 by -$0.03.

Is Akari Therapeutics PLC (ADR) overvalued?

According to Wall Street analysts Akari Therapeutics PLC (ADR)’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Akari Therapeutics PLC (ADR) pay dividends?

Akari Therapeutics PLC (ADR) does not currently pay dividends.

What is Akari Therapeutics PLC (ADR)’s EPS estimate?

Akari Therapeutics PLC (ADR)’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Akari Therapeutics PLC (ADR) have?

Akari Therapeutics PLC (ADR) has 32,612,576 shares outstanding.

What happened to Akari Therapeutics PLC (ADR)’s price movement after its last earnings report?

Akari Therapeutics PLC (ADR) reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.09. Following the earnings report the stock price went up 0.901%.

Which hedge fund is a major shareholder of Akari Therapeutics PLC (ADR)?

Currently, no hedge funds are holding shares in AKTX

Akari Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-112.22%

Trailing 12-Months

Asset Growth

902.97%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Akari Therapeutics PLC (ADR)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Akari Therapeutics (AKTX) Earnings & Revenues

Historic Earnings Reports

AKTX Stock 12 Month Forecast

Average Price Target

$4.53

▲(331.43% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"36":"$36","-1":"-$1","8.25":"$8.25","17.5":"$17.5","26.75":"$26.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,8.25,17.5,26.75,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2021","6":"Nov<br/>2024","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.7,1.1846153846153846,1.669230769230769,2.1538461538461537,2.6384615384615384,3.1230769230769226,3.6076923076923073,4.092307692307692,4.576923076923077,5.061538461538461,5.546153846153846,6.030769230769231,6.515384615384615,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.7,0.9946153846153846,1.2892307692307692,1.583846153846154,1.8784615384615384,2.1730769230769234,2.4676923076923076,2.762307692307692,3.056923076923077,3.3515384615384614,3.6461538461538465,3.940769230769231,4.235384615384615,{"y":4.53,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.7,0.7692307692307692,0.8384615384615384,0.9076923076923077,0.9769230769230769,1.046153846153846,1.1153846153846154,1.1846153846153846,1.2538461538461538,1.323076923076923,1.3923076923076922,1.4615384615384617,1.5307692307692307,{"y":1.6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":35.9,"date":1596240000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.9,"date":1598918400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.9,"date":1617235200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.6,"date":1625097600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.42,"date":1667260800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.6,"date":1669852800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.78,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >